Dr Hoos is Senior Vice President, R&D Governance Chair, and Therapeutic Area (TA) Head for Oncology at GlaxoSmithKline Pharmaceuticals (GSK). At GSK he leads technical and funding decisions in R&D as well as Discovery and Development in Oncology and in immuno-oncology, epigenetics, cell therapy, and synthetic lethality. Dr Hoos also serves as Chairman of the Board of Trustees of the Sabin Vaccine Institute (SVI), Director on the Board of TCR2, Co-Founder and Director on the Board of Imugene, Co-Director of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI). Previously, Dr Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipitimumab). Before BMS, Dr. Hoos was Senior Director of Clinical Development at Agenus Bio (former Antigenics). He is Member of Risk Committee.